Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
237 hedge funds and large institutions have $2.8B invested in Amicus Therapeutics in 2021 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 82 increasing their positions, 77 reducing their positions, and 26 closing their positions.
50% more call options, than puts
Call options by funds: $19.9M | Put options by funds: $13.2M
19% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 26
5.78% more ownership
Funds ownership: 104.09% → 109.87% (+5.8%)
6% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 77
5% more capital invested
Capital invested by funds: $2.67B → $2.8B (+$130M)
1% more funds holding
Funds holding: 235 → 237 (+2)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$88.2M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$53.5M |
| 3 |
PA
Perceptive Advisors
New York
|
+$35.2M |
| 4 |
AG
Artal Group
Luxembourg
|
+$30.1M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$21.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$37.3M |
| 2 |
DM
Deerfield Management
New York
|
-$28.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.8M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12.6M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$11.2M |
FOLD Hedge Fund Activity: Q3 2021 in Review
237 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2021, worth a combined $2.8B — up 4.9% from $2.67B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new FOLD positions and 26 closed out — a net gain of 5 holders — while 82 added to existing stakes and 77 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $88.2M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $37.3M sold.
- 237 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2021, up from 235 in Q2 2021.
- Funds reported $2.8B of Amicus Therapeutics stock for Q3 2021, up 4.9% quarter-over-quarter.
- 31 funds opened new Amicus Therapeutics positions in Q3 2021 and 26 closed out, a net change of +5 holders.
- The largest Amicus Therapeutics buyer in Q3 2021 was Wellington Management Group, an estimated $88.2M added.
- The largest Amicus Therapeutics seller in Q3 2021 was Point72 Asset Management, an estimated $37.3M sold.
Based on aggregated 13F filings for Q3 2021.